News

Akorn has posted a net income of $3.99m for the third quarter 2010, or $0.04 per diluted share, compared to net loss of $5.1m, or $0.06 loss per

VGX-3100 is a therapeutic vaccine for cervical dysplasia and cancer. The grant will also support Inovio Pharma’s development projects for Syncon universal flu and dengue vaccines. The PPACA

Boehringer is expected to make available the 75mg dose of Pradaxa in pharmacies in the coming weeks. Pradaxa received approval from the US Food and Drug Administration (FDA)

The Talent Captivia System is indicated specifically for the endovascular repair of fusiform aneurysms and saccular aneurysms/penetrating ulcers of the descending thoracic aorta in patients having appropriate anatomy.

Beckley is expected to oversee LDM Group’s high-performance pharmacy and EMR teams, manage key initiatives, and develop sales and new business strategies for future growth opportunities in the

Seattle Genetics has posted a net loss of $34.86m for the third quarter 2010, or $0.34 loss per diluted share, compared to $19.83m, or $0.21 loss per diluted

Parexel has posted a net income of $17.79m for the first quarter 2010, or $0.3 per diluted share, compared to $12.44m, or $0.21 per diluted share, for the

NextGen Healthcare Information Systems, a wholly owned subsidiary of Quality Systems, provides integrated clinical, financial and connectivity solutions for ambulatory, inpatient and dental provider organizations. As per the

The trial, also referred to as Response, is a global, randomised study of efficacy and safety in polycythemia vera patients who are resistant or intolerant of hydroxyurea. Response